摘要
中药复方对于原发性肝癌具有独特的临床疗效和优势,但复方成分复杂,靶点众多,部分限制中药复方研究的现代化进程,但近几年的机制研究也取得了一定的成果,具体涉及抑制增殖、诱导周期阻滞和凋亡、抑制黏附侵袭、抑制血管生成、调节免疫、增效减毒、逆转耐药等方面,该文现就实验研究进展作简要综述。
For primary liver cancer, Chinese herbal compound has unique clinical efficacy and advantages. It is known that complex components and numerous targets, which partly confines the modernization progress of Chinese herbal compound research. But achievements have been made in recent years, referring to growth inhibitory, cycle arrest and apoptosis induction, angiogenesis inhibitory, immune adjustment, improving effect and decreasing toxicity, reversing the drug-resistance and other respects. The experimental research progress is mainly reviewed in this article.
出处
《辽宁中医药大学学报》
CAS
2017年第8期152-155,共4页
Journal of Liaoning University of Traditional Chinese Medicine
基金
国家自然科学基金重点项目(81430101)
国家自然科学基金面上项目(81273881
81473487)
上海市自然科学基金项目(14ZR1408400)
关键词
中药复方
原发性肝癌
实验研究
进展
Chinese herbal compound
primary liver cancer
experimental study
progress